ÂÜÀòÂÒÂ×

Rahul Kakkar is a seasoned medical professional and entrepreneur with a diverse background in academia, clinical practice, and the biotechnology sector. Currently, Kakkar serves as a Board Member at Attralus and holds the position of Lecturer in Medicine and Associate Physician at Harvard Medical School and Brigham and Women's Hospital, respectively. Kakkar has significant leadership experience, including roles as President and CEO of Tome Biosciences and CEO of Pandion Therapeutics, where a notable IPO occurred in July 2020 prior to its acquisition by Merck. Kakkar also co-founded Corvidia Therapeutics, which was acquired by Novo Nordisk in June 2020. Early career highlights include serving as an Intensive Care Physician at Winchester Hospital and a Director for Emerging Innovations at AstraZeneca. Kakkar earned an MD from Tufts University School of Medicine and a BA in Art and Architectural History from Tufts University.